Status:
UNKNOWN
Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Lead Sponsor:
Fundación de investigación HM
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
CMV
Eligibility:
All Genders
18+ years
Brief Summary
Cytomegalovirus (CMV) is the most common member of the herpes viruses to infect humans. Its double-stranded linear DNA duplex contains 165 genes that encode viral proteins that mimic and interact with...
Detailed Description
Evidence in the literature has demonstrated how different factors have been associated with CMV disease; however, the effect of new anticancer therapies (personalized chemotherapies, biological and im...
Eligibility Criteria
Inclusion
- age \>=18 y.o.,
- admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation.
Exclusion
- survival expectation previous to ICU admission less than 6 months,
- intubation after 12 hours of ICU admission
- limitation of the therapeutic effort previous or during the ICU stay,
- admission to the ICU during the previous 3 months
- not agreeing to sign an informed consent.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04280380
Start Date
March 1 2020
End Date
December 31 2022
Last Update
February 21 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.